|Other Info:||Manufactured in France by : SEPTODONT, France.Distributed by : SEPTODONT, Inc.,245, Quigley Boulevard-Suite CNew Castle, Delaware 19720® 05 14 228 50 0302/02|
ACCIDENTAL INTRAVASCULAR INJECTION MAY BE ASSOCIATED WITH CONVULSIONS, FOLLOWED BY CENTRAL NERVOUS SYSTEM OR CARDIORESPIRATORY DEPRESSION AND COMA, PROGRESSING ULTIMATELY TO RESPIRATORY ARREST.
DENTAL PRACTITIONERS AND/OR CLINICIANS WHO EMPLOY LOCAL ANESTHETIC AGENTS SHOULD BE WELL VERSED IN DIAGNOSIS AND MANAGEMENT OF EMERGENCIES THAT MAY ARISE FROM THEIR USE.
RESUSCITATIVE EQUIPMENT, OXYGEN, AND OTHER RESUSCITATIVE DRUGS SHOULD BE AVAILABLE FOR IMMEDIATE USE.Intravascular injections should be avoided.
To avoid intravascular injection, aspiration should be performed before Septocaine® is injected.
The needle must be repositioned until no return of blood can be elicited by aspiration.
Note, however, that the absence of blood in the syringe does not guarantee that intravascular injection has been avoided.Septocaine® contains epinephrine that can cause local tissue necrosis or systemic toxicity.
Usual precautions for epinephrine administration should be observed.Septocaine® contains sodium metabisulfite, a sulfite that may cause allergic-type reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people.
The overall prevalence of sulfite sensitivity in the general population is unknown.Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.